zuloocode.blogg.se - Labcorp sequential screening

#Labcorp sequential screening plus#

Pregnancy-associated plasma protein A (PAPP-A).Use of the following serum markers for second trimester serum marker screening for Down syndrome because the clinical use of these markers is under investigation:.Use of urinary markers (measurement of cell-free DNA and metabolomic profiling) for testing for fetal aneuploidy (trisomy 13, 18 and 21) in pregnant women.Use of serum markers A Disintegrin And Metalloprotease 12 (ADAM 12) and placental protein 13 (PP13) for first trimester screening for Down syndrome.Use of maternal serum anti-Mullerian hormone level for first or second trimester screening for Down syndrome.

Unity Screen (BillionToOne) for testing single-gene disorders.

Single and multi-gene screening by prenatal cell-free fetal DNA (e.g., PreSeek, Vistara).

Measurement of circulating fetal nucleated red blood cells and extra-villous trophoblastsis for non-invasive prenatal diagnosis of fetal aneuploidy.

MaterniT Genome, Panorama with microdeletions, Qnatal Advanced with optional microdeletions), and for other indications not listed above

Measurement of cell-free DNA for fetal genotyping for RHD (e.g., Sensigene), screening of micro-deletion syndrome, micro-duplication syndrome, and rare autosomal trisomies (e.g., trisomy 2, 5, 7, 8 (Warkany syndrome 2), 9, 12, 14, 15, 16, 17 and 22) (e.g.

Maternal Fetal Screen I T1 (Eurofins NTD, LLC).

Evaluation of DSCR4 gene methylation in plasma for non-invasive prenatal diagnosis of fetal aneuploidy.

The following procedures are considered experimental and investigational because the effectiveness of these approaches has not been established:

Aetna considers NIPT not medically necessary for pregnant women who have previously had a multiple serum marker screening test with or without fetal nuchal translucency ultrasound that is negative for fetal aneuploidy during the current pregnancy.

#Labcorp sequential screening plus#

Aetna considers non-invasive prenatal testing (NIPT) using measurement of cell-free fetal nucleic acids in maternal blood (e.g., ClariTest Core (chr 21, 18,13, X,Y), MaterniT21 PLUS Core (chr21, 18, 13) NO Gender, MaterniT21 PLUS Core (chr21, 18, 13, X, Y), Panorama Prenatal Test (chr21, 18, 13, X, Y only), QNatal Advanced (21, 18, 13, X and Y), Verifi Prenatal Test) medically necessary for screening for fetal aneuploidy (trisomy 13, 18 and 21) in all pregnant women.Multiple serum marker testing is considered medically necessary for women who decline these more invasive procedures. Preventive Services Task Force and the American College of Obstetricians and Gynecologists, women aged 35 and older who desire information of their risk of having a Down syndrome fetus should have chorionic villus sampling (CVS) or amniocentesis for detection. This Clinical Policy Bulletin addresses serum and urine marker screening for fetal aneuploidy.Īetna considers multiple serum marker testing (dimeric inhibin A, human chorionic gonadotropin (hCG) with maternal serum alpha-fetoprotein (MSAFP), and unconjugated estriol) medically necessary for pregnant women who have been adequately counseled and who desire information on their risk of having a Down syndrome fetus.Īccording to recommendations of the U.S. Number: 0464 Table Of Contents Policy Applicable CPT / HCPCS / ICD-10 Codes Background References